On September 26th, Gelonhui reported that wuhan easy diagnosis biomedicine (002932.SZ) announced that as of September 25, 2024, the company has cumulatively repurchased 9,369,869 shares of the company through a repurchase special securities account through centralized bidding, accounting for 4.03% of the total share capital of the company; the highest fill price for repurchasing shares was 20.98 yuan/share, the lowest fill price was 15.33 yuan/share, and the total fill amount was RMB 178,950,212.47 (excluding trading taxes and fees). The source of funds for this share repurchase is the company's own funds, and the repurchase price did not exceed the price ceiling set in the repurchase plan of 22.88 yuan/share (according to the company's share repurchase plan, from the date of the annual equity distribution ex-rights ex-dividend in 2023 (May 28, 2024), the company's repurchase price ceiling was adjusted from 23 yuan/share to 22.88 yuan/share).